Savara与Rtw达成7500万美元的特许权资助协议,以支持Molbreevi*在自身免疫性肺泡蛋白沉积症(Autoimmune Pap)中的潜在上市。
Savara与Rtw达成7500万美元的特许权资助协议,以支持Molbreevi*在自身免疫性肺泡蛋白沉积症(Autoimmune Pap)中的潜在上市。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.